KRAS G12D Mutations

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Ranok TherapeuticsChina - Hangzhou

1 program

RNK08954Phase 21 trial

Active Trials

NCT07303465Recruiting60Est. Nov 2026

GenFleet TherapeuticsChina - Shanghai

1 program

GFH375Phase 1/22 trials

Active Trials

NCT07554859Not Yet Recruiting90Est. Apr 2028

NCT06500676Recruiting407Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2024

2025

2026

2027

2028

GenFleet TherapeuticsGFH375

Ranok TherapeuticsRNK08954

GenFleet TherapeuticsGFH375

Clinical Trials (3)

Total enrollment: 557 patients across 3 trials

NCT07554859 GenFleet TherapeuticsGFH375

GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

Start: May 2026Est. completion: Apr 202890 patients

Phase 2Not Yet Recruiting

NCT07303465 Ranok TherapeuticsRNK08954

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Start: Oct 2025Est. completion: Nov 202660 patients

Phase 2Recruiting

NCT06500676 GenFleet TherapeuticsGFH375

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Start: Jul 2024Est. completion: Dec 2028407 patients

Phase 1/2Recruiting

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 557 patients

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.